About the conference
Breast cancer is a highly heterogeneous disease, with different molecular subtypes. Insights into tumor biology of breast cancer have led the path towards the introduction of targeted treatment approaches Luminal-type and Basal-like/Triple Negative breast cancers which have been shown to be completely different diseases at the molecular level, as well as in terms of the course of the disease, patient prognosis and survival.
While the luminal subtype, characterized by the expression of estrogen and/or progesterone receptors (ER/PR) and basal-like/TN phenotypes exhibit a wider and more continuous spectrum of genomic evolution mostly linked to BRCA gene mutation with great therapeutic implications. Besides the ER, targeting HER2 is today regarded as the best established targeted treatment approach in early and metastatic BC .TNBC (triple negative breast cancer) is characterized by a high mutational load, which is apparently associated with a high immunogenicity, making TNBC an attractive field for developing immunotherapy in breast cancer. With recent results from clinical trials targeting well-known breast cancer-promoting pathways, a lot of drugs are now under development to improve patient outcomes. This symposium summarizes current new breast cancer therapeutic aspects including updates in reconstructive surgeries and shed light on translational aspects of breast cancer research.
